Related references
Note: Only part of the references are listed.BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy
Rameswari Chilamakuri et al.
TRANSLATIONAL ONCOLOGY (2022)
Rethinking high-risk neuroblastoma treatment
Susan L. Cohn et al.
PEDIATRIC BLOOD & CANCER (2022)
Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
Kristina Ihrmark Lundberg et al.
CURRENT ONCOLOGY REPORTS (2022)
Mechanisms of APOBEC3 mutagenesis in human cancer cells
Mia Petljak et al.
NATURE (2022)
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
Diana Treis et al.
JCO PRECISION ONCOLOGY (2022)
The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets
Sepideh Mirzaei et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Metabolic Aspects of Anthracycline Cardiotoxicity
Michele Russo et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133-nonstem cell population in hepatocellular carcinoma cell line, HuH-7
Mustafa Karabicici et al.
MOLECULAR ONCOLOGY (2021)
CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity
Shigeaki Sunada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Effimia Christidi et al.
CELL DEATH & DISEASE (2021)
A comprehensive review on time-tested anticancer drug doxorubicin
Sruthi Sritharan et al.
LIFE SCIENCES (2021)
Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines
Tania Capeloa et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Inhibition of Non-Receptor Tyrosine Kinase JAK2 Reduces Neuroblastoma Cell Growth and Enhances the Action of Doxorubicin
T. D. Lebedev et al.
MOLECULAR BIOLOGY (2020)
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
Harriet E. D. Southgate et al.
FRONTIERS IN ONCOLOGY (2020)
AMPK-mediated activation of MCU stimulates mitochondrial Ca2+ entry to promote mitotic progression
Haixin Zhao et al.
NATURE CELL BIOLOGY (2019)
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
Claudia Christowitz et al.
BMC CANCER (2019)
Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
Amanda J. Stolarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Endoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic cell
Wataru R. Yamamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells
James H. Doroshow
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Cancer stem cells in neuroblastoma therapy resistance
Natarajan Aravindan et al.
CANCER DRUG RESISTANCE (2019)
The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
Antonietta Rosella Farina et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy
Yun Sun Lee et al.
TUMOR BIOLOGY (2018)
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
Holly L. Pacenta et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases
Zhi-Hong Yu et al.
CHEMICAL REVIEWS (2018)
Telomerase and drug resistance in cancer
Natalia Lipinska et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
DS16570511 is a small-molecule inhibitor of the mitochondrial calcium uniporter
Naohiro Kon et al.
CELL DEATH DISCOVERY (2017)
Cycling hypoxia: A key feature of the tumor microenvironment
Carine Michiels et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response
Dadi Jiang et al.
SCIENTIFIC REPORTS (2016)
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients
Dirk Fey et al.
SCIENCE SIGNALING (2015)
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients
Dirk Fey et al.
SCIENCE SIGNALING (2015)
Ryanodine receptors: physiological function and deregulation in Alzheimer disease
Dolores Del Prete et al.
MOLECULAR NEURODEGENERATION (2014)
The TrkAIII Oncoprotein Inhibits Mitochondrial Free Radical ROS-Induced Death of SH-SY5Y Neuroblastoma Cells by Augmenting SOD2 Expression and Activity at the Mitochondria, within the Context of a Tumour Stem Cell-like Phenotype
Pierdomenico Ruggeri et al.
PLOS ONE (2014)
Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
Guan Wang et al.
PLOS ONE (2013)
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation
Robert A. Forrest et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Ryanodine Receptor Blockade Reduces Amyloid-β Load and Memory Impairments in Tg2576 Mouse Model of Alzheimer Disease
Benedicte Oules et al.
JOURNAL OF NEUROSCIENCE (2012)
Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
Pierre Mazot et al.
PLOS ONE (2012)
Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1
Bray Denard et al.
ELIFE (2012)
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
Susan K. Peirce et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside
Munira Shabbir et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Trk activation in the secretory pathway promotes Golgi fragmentation
Leslayann C. Schecterson et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2010)
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
H. Christian Reinhardt et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
The Alternative TrkAIII Splice Variant Targets the Centrosome and Promotes Genetic Instability
Antonietta Rosella Farina et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells
A. R. Farina et al.
ONCOGENE (2009)
Characterization of class I and II ADP-ribosylation factors (Arfs) in live cells:: GDP-bound class II Arfs associate with the ER-Golgi intermediate compartment independently of GBF1
Justin Chun et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
IP3 receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis
F. Splettstoesser et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Exploring the specificity of the PI3K family inhibitor LY294002
Severine I. Gharbi et al.
BIOCHEMICAL JOURNAL (2007)
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Lyubomir T. Vassilev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Trk is a calmodulin-binding protein: implications for receptor processing
M Llovera et al.
JOURNAL OF NEUROCHEMISTRY (2004)
TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma
A Tacconelli et al.
CANCER CELL (2004)
Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells
MA Emran et al.
CANCER LETTERS (2002)
Doxorubicin directly binds to the cardiac-type ryanodine receptor
K Saeki et al.
LIFE SCIENCES (2002)
Antioxidative activity of natural isorhapontigenin
QL Wang et al.
JAPANESE JOURNAL OF PHARMACOLOGY (2001)
Factors secreted by human neuroblastoma mediate doxorubicin resistance by activating STAT3 and inhibiting apoptosis
A Rebbaa et al.
MOLECULAR MEDICINE (2001)
Dantrolene inhibition of ryanodine receptor Ca2+ release channels -: Molecular mechanism and isoform selectivity
FY Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor
JC Arevalo et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
